Skip to main content

Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 4:00 p.m. ET.

A live webcast will be accessible on the Investor page of Travere’s website at ir.travere.com/events-and-presentations, and a replay will be available for up to 30 days following the event.

About Travere Therapeutics

At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.

Travere Therapeutics will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 4:00 p.m. ET.

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  268.84
+3.83 (1.45%)
AAPL  304.60
+2.35 (0.78%)
AMD  445.07
-2.51 (-0.56%)
BAC  51.28
+0.05 (0.10%)
GOOG  386.83
+1.93 (0.50%)
META  608.90
+3.84 (0.63%)
MSFT  418.16
-2.90 (-0.69%)
NVDA  221.30
-2.17 (-0.97%)
ORCL  191.49
+3.33 (1.77%)
TSLA  422.86
+5.60 (1.34%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.